Skip to main content
Erschienen in: Journal of General Internal Medicine 3/2020

03.11.2020 | Perspective

Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration

verfasst von: Kelsey C. Priest, PhD, MPH, Dennis McCarty, PhD, Travis I. Lovejoy, PhD, MPH

Erschienen in: Journal of General Internal Medicine | Sonderheft 3/2020

Einloggen, um Zugang zu erhalten

Abstract

To mitigate morbidity and mortality of the drug-related overdose crisis, the Veterans Health Administration (VHA) can increase access to treatments that save lives—medications for opioid use disorder (MOUD). Despite an increasing need, MOUD continues to be underutilized due to multifaceted barriers that exist within broader macro- and microenvironments. To promote MOUD utilization, policymakers and healthcare leaders should (1) identify and implement person-centered MOUD delivery systems (e.g., the Medication First Model, community-informed design); (2) recognize and address MOUD delivery gaps (e.g., the Best-Practice in Oral Opioid Agonist Collaborative); (3) broaden the definition of the MOUD delivery system (e.g., access to MOUD in non-clinical settings); and (4) expand MOUD options (e.g., injectable opioid agonist therapy). Increasing access to MOUD is not a singular fix to the overdose-related crisis. It is, however, a possible first step to mitigate harm, and save lives.
Literatur
1.
Zurück zum Zitat Finlay AK, Binswanger IA, Timko C, et al. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: implications for implementation science. J Subst Abus Treat 2018;95:43-47.CrossRef Finlay AK, Binswanger IA, Timko C, et al. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: implications for implementation science. J Subst Abus Treat 2018;95:43-47.CrossRef
2.
Zurück zum Zitat Madras BK, Ahmad NJ, Wen J, Sharfstein J. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspectives 2020. Madras BK, Ahmad NJ, Wen J, Sharfstein J. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspectives 2020.
3.
Zurück zum Zitat Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abus 2018;39(2):139-144.CrossRef Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abus 2018;39(2):139-144.CrossRef
4.
Zurück zum Zitat James K, Jordan A. The opioid crisis in black communities. The Journal of Law, Medicine & Ethics 2018;46(2):404-421.CrossRef James K, Jordan A. The opioid crisis in black communities. The Journal of Law, Medicine & Ethics 2018;46(2):404-421.CrossRef
5.
Zurück zum Zitat Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA psychiatry 2019;76(9):979-981.CrossRef Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA psychiatry 2019;76(9):979-981.CrossRef
6.
Zurück zum Zitat Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med 2019;16(11). Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med 2019;16(11).
7.
Zurück zum Zitat Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus 2019;41(1):110-120.CrossRef Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus 2019;41(1):110-120.CrossRef
8.
Zurück zum Zitat Santana MJ, Manalili K, Jolley RJ, Zelinsky S, Quan H, Lu M. How to practice person-centred care: a conceptual framework. Health Expect 2018;21(2):429-440.CrossRef Santana MJ, Manalili K, Jolley RJ, Zelinsky S, Quan H, Lu M. How to practice person-centred care: a conceptual framework. Health Expect 2018;21(2):429-440.CrossRef
9.
Zurück zum Zitat Marchand K, Beaumont S, Westfall J, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Substance Abuse Treatment, Prevention, and Policy 2019;14(1):37.CrossRef Marchand K, Beaumont S, Westfall J, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Substance Abuse Treatment, Prevention, and Policy 2019;14(1):37.CrossRef
10.
Zurück zum Zitat Winograd RP, Presnall N, Stringfellow E, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse 2019;45(4):333-340.CrossRef Winograd RP, Presnall N, Stringfellow E, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse 2019;45(4):333-340.CrossRef
11.
Zurück zum Zitat Substance Abuse and Mental Health Services Administration. The Opioid Crisis and the Black/African American Population: An Urgent Issue. 2020. Substance Abuse and Mental Health Services Administration. The Opioid Crisis and the Black/African American Population: An Urgent Issue. 2020.
12.
Zurück zum Zitat Tsemberis S. Housing first: The pathways model to end homelessness for people with mental illness and addiction manual. European Journal of Homelessness. 2011;5(2). Tsemberis S. Housing first: The pathways model to end homelessness for people with mental illness and addiction manual. European Journal of Homelessness. 2011;5(2).
13.
Zurück zum Zitat Winograd RP, Wood CA, Stringfellow EJ, et al. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abus Treat 2020;108:55-64.CrossRef Winograd RP, Wood CA, Stringfellow EJ, et al. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abus Treat 2020;108:55-64.CrossRef
14.
Zurück zum Zitat Hansen H, Roberts SK. Two tiers of biomedicalization: Methadone, buprenorphine, and the racial politics of addiction treatment. Adv Med Sociol 2012;14(12):79-102.CrossRef Hansen H, Roberts SK. Two tiers of biomedicalization: Methadone, buprenorphine, and the racial politics of addiction treatment. Adv Med Sociol 2012;14(12):79-102.CrossRef
16.
Zurück zum Zitat Beamish L, Sagorin Z, Stanley C, et al. Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting. BMC Health Serv Res. 2019;19(1):1-8.CrossRef Beamish L, Sagorin Z, Stanley C, et al. Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting. BMC Health Serv Res. 2019;19(1):1-8.CrossRef
17.
Zurück zum Zitat The Institute for Healthcare Improvement. The breakthrough series: IHI’s collaborative model for achieving breakthrough improvement. 2003. The Institute for Healthcare Improvement. The breakthrough series: IHI’s collaborative model for achieving breakthrough improvement. 2003.
20.
Zurück zum Zitat Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus 2020;41(3):275-282.CrossRef Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus 2020;41(3):275-282.CrossRef
21.
Zurück zum Zitat Priest KC, Lovejoy TI, Englander H, Shull S, McCarty D. Opioid agonist therapy during hospitalization within the Veterans Health Administration: a pragmatic retrospective cohort analysis. J Gen Intern Med. 2020. Priest KC, Lovejoy TI, Englander H, Shull S, McCarty D. Opioid agonist therapy during hospitalization within the Veterans Health Administration: a pragmatic retrospective cohort analysis. J Gen Intern Med. 2020.
22.
Zurück zum Zitat Priest KC, McCarty D. Role of the hospital in the 21st Century opioid overdose epidemic: the addiction medicine consult service. J Addict Med. 2019;13(2):104–112. Priest KC, McCarty D. Role of the hospital in the 21st Century opioid overdose epidemic: the addiction medicine consult service. J Addict Med. 2019;13(2):104–112.
23.
Zurück zum Zitat Snow RL, Simon RE, Jack HE, Oller D, Kehoe L, Wakeman SE. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic. J Subst Abus Treat 2019. Snow RL, Simon RE, Jack HE, Oller D, Kehoe L, Wakeman SE. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic. J Subst Abus Treat 2019.
24.
Zurück zum Zitat D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644.CrossRef D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644.CrossRef
25.
Zurück zum Zitat McGuire AB, Powell KG, Treitler PC, et al. Emergency department-based peer support for opioid use disorder: emergent functions and forms. J Subst Abus Treat 2020;108:82-87.CrossRef McGuire AB, Powell KG, Treitler PC, et al. Emergency department-based peer support for opioid use disorder: emergent functions and forms. J Subst Abus Treat 2020;108:82-87.CrossRef
27.
Zurück zum Zitat National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press; 2019. National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press; 2019.
28.
Zurück zum Zitat McNeil R, Small W, Wood E, Kerr T. Hospitals as a ‘risk environment’: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Social science & medicine (1982) 2014;105:59-66.CrossRef McNeil R, Small W, Wood E, Kerr T. Hospitals as a ‘risk environment’: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Social science & medicine (1982) 2014;105:59-66.CrossRef
29.
Zurück zum Zitat Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend 2019;198:80-86.CrossRef Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend 2019;198:80-86.CrossRef
31.
Zurück zum Zitat Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addiction science & clinical practice 2019;14(1):20.CrossRef Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addiction science & clinical practice 2019;14(1):20.CrossRef
32.
Zurück zum Zitat Hood JE, Banta-Green CJ, Duchin JS, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Subst Abus 2019:1-9. Hood JE, Banta-Green CJ, Duchin JS, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Subst Abus 2019:1-9.
33.
Zurück zum Zitat Priest KC. The COVID-19 pandemic: practice and policy considerations for patients with opioid use disorder. Health Affairs Blog. 2020. Priest KC. The COVID-19 pandemic: practice and policy considerations for patients with opioid use disorder. Health Affairs Blog. 2020.
34.
Zurück zum Zitat Samuels EA, Clark SA, Wunsch C, et al. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020. Samuels EA, Clark SA, Wunsch C, et al. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020.
35.
Zurück zum Zitat Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020. Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020.
36.
Zurück zum Zitat Iheanacho T, Payne K, Tsai J. Mobile, Community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: a pilot, feasibility study. The American Journal on Addictions. 2020. Iheanacho T, Payne K, Tsai J. Mobile, Community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: a pilot, feasibility study. The American Journal on Addictions. 2020.
37.
Zurück zum Zitat Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy 2019;74:257-265.CrossRef Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy 2019;74:257-265.CrossRef
38.
Zurück zum Zitat Fairbairn N, Ross J, Trew M, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ : Canadian Medical Association journal=journal de l'Association medicale canadienne. 2019;191(38):E1049-E1056.CrossRef Fairbairn N, Ross J, Trew M, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ : Canadian Medical Association journal=journal de l'Association medicale canadienne. 2019;191(38):E1049-E1056.CrossRef
39.
Zurück zum Zitat British Columbia Centre on Substance Use. Risk mitigation: in the context of dual public health emergencies. 2020. British Columbia Centre on Substance Use. Risk mitigation: in the context of dual public health emergencies. 2020.
Metadaten
Titel
Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration
verfasst von
Kelsey C. Priest, PhD, MPH
Dennis McCarty, PhD
Travis I. Lovejoy, PhD, MPH
Publikationsdatum
03.11.2020
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe Sonderheft 3/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06266-3

Weitere Artikel der Sonderheft 3/2020

Journal of General Internal Medicine 3/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.